In this study, we assessed the efficacy and safety of ruxolitinib in controlling disease in patients with polycythaemia vera without splenomegaly who need second-line therapy.

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study / Passamonti, Francesco; Griesshammer, Martin; Palandri, Francesca; Egyed, Miklos; Benevolo, Giulia; Devos, Timothy; Callum, Jeannie; Vannucchi, Alessandro M; Sivgin, Serdar; Bensasson, Caroline; Khan, Mahmudul; Mounedji, Nadjat; Saydam, Guray. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - ELETTRONICO. - 18:(2017), pp. 88-99. [10.1016/S1470-2045(16)30558-7]

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

VANNUCCHI, ALESSANDRO MARIA;
2017

Abstract

In this study, we assessed the efficacy and safety of ruxolitinib in controlling disease in patients with polycythaemia vera without splenomegaly who need second-line therapy.
2017
18
88
99
Goal 3: Good health and well-being for people
Passamonti, Francesco; Griesshammer, Martin; Palandri, Francesca; Egyed, Miklos; Benevolo, Giulia; Devos, Timothy; Callum, Jeannie; Vannucchi, Alessandro M; Sivgin, Serdar; Bensasson, Caroline; Khan, Mahmudul; Mounedji, Nadjat; Saydam, Guray
File in questo prodotto:
File Dimensione Formato  
passamonti lanc oncol 2017.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 557.12 kB
Formato Adobe PDF
557.12 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1084509
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 189
  • ???jsp.display-item.citation.isi??? 190
social impact